HIV-1 sub- type distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics

Authors: Abecasis AB, Albert J, Åsjö B, Balotta C, Beshkov D, Boucher CA, Camacho RJ, Clotet B, De Gascun C, Griskevicius A, Grossman Z, Hamouda O, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Kücherer C, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Staneková D, Stanojevic M, Struck D, Theys K, Van de Vijver DMC, Vandamme AM, Vercauteren J, Wensing AMJ
Publication Year: 2013
Journal: Retrovirology
Link: http://www.retrovirology.com/content/10/1/7

Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures and clinical decisions. Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes.
Read More

Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure

Authors: Abecasis A, Cabanas J, Camacho RJ, Gomes P, Libin P, Theys K, Van Laethem K
Publication Year: 2015
Journal: Journal of Clinical Virology
Link: http://www.ncbi.nlm.nih.gov/pubmed/26305833

BACKGROUND: Dolutegravir is approved for the treatment of HIV-1 patients exposed to other integrase inhibitors, but the decision to use dolutegravir in this setting should be informed by drug resistance testing. OBJECTIVES: This study determined the extent of disagreement in predicted residual dolutegravir activity after raltegravir use, and identified individual mutational patterns for which uncertainty […]
Read More

Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine

Authors: Camacho RJ, Gomes P, Portuguese HIVRSG, Rhee SY, Theys K, Vandamme AM
Publication Year: 2015
Journal: Clinical Microbiology and Infection
Link: http://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(15)00299-2/fulltext%20

Rilpivirine is a second-generation nonnucleoside reverse-transcriptase inhibitor (NNRTI) currently indicated for first-line therapy, but its clinical benefit for HIV-1 infected patients failing first-generation NNRTIs is largely undefined. This study quantified the extent of genotypic rilpivirine resistance in viral isolates from 1212 patients upon failure of efavirenz- or nevirapine-containing antiretroviral treatment, of whom more than respectively […]
Read More

Characterization of amino acids Arg, Ser and Thr at position 70 within HIV-1 reverse transcriptase

Authors: Bernatchez J, Camacho RJ, Covens K, De Wit S, Dekeersmaeker N, Götte M, Megens S, Theys K, Van Laethem K, Vandamme AM, Vinken L
Publication Year: 2014
Journal: Acta Clinica Belgica
Link: http://www.ncbi.nlm.nih.gov/pubmed/25103592

The amino acid position 70 in HIV-1 reverse transcriptase (RT) plays an important role in nucleoside RT inhibitor (NRTI) resistance. K70R is part of the thymidine analog mutations, but also other amino acid changes have been associated with NRTI resistance, such as K70E and K70G. In this study, we investigated the in vivo selection of the HIV-1 RT mutations K70S and K70T and their in vitro effect on drug resistance and replication capacity.
Read More

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

Authors: Abecasis AB, Albert J, Åsjö B, Balotta C, Beshkov D, Boucher CA, Camacho RJ, Clotet B, Coughlan S, Frentz D, Griskevicius A, Grossman Z, Hamouda O, Horban A, Jørgensen LB, Kolupajeva T, Korn K, Kostrikis LG, Kücherer C, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Staneková D, Stanojevic M, Struck D, Van de Vijver DA, Van Wijngaerden E, Vercauteren J, Wensing AMJ
Publication Year: 2014
Journal: BMC Infectious Diseases
Link: http://www.biomedcentral.com/1471-2334/14/407

One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program.
Read More

HIV-1 sub- type distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics

Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure

Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine

Characterization of amino acids Arg, Ser and Thr at position 70 within HIV-1 reverse transcriptase

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

About GHTM

Contacts

Funding